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A Sunscreen’s Labeled Sun Protection Factor May
Overestimate Protection at Temperate Latitudes:
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We lack comparative data on sunscreens with comparable sun protection factors (SPFs), but with different levels
of UVA protection, especially against cumulative erythema from repeated suberythemal exposure. Thus, we
compared the protection from cumulative sunburn with two sunscreens labeled SPF 6, but with different UVR-
absorbing properties, one that absorbs the UVB waveband and the other that absorbs UVBþUVA wavebands.
We simulated sunlight typical of temperate latitudes to expose skin daily to suberythemal doses for 13
consecutive days. The study population consisted of eight fair-skinned sun-sensitive healthy young adults.
Erythema was assessed by eye and objectively, and the SPF of each sunscreen was modeled with changes in
solar UVR with time of day and latitude. The broad-spectrum sunscreen gave much better protection against
cumulative erythema than the UVB sunscreen. The explanation for this is that UVA makes a greater contribution
toward sunburn at temperate latitudes than under the laboratory conditions in which SPF is tested and
assigned. The data support the current trend toward broad-spectrum sunscreen protection. They also show that
labeled SPF is much more reliable with broad-spectrum sunscreens because SPF with primarily UVB sunscreens
is dependent on time of day and latitude.
JID JOURNAL CLUB ARTICLE: For questions, answers, and open discussion about this article, please go to http://www.nature.com/jid/journalclub
Journal of Investigative Dermatology (2010) 130, 2457–2462; doi:10.1038/jid.2010.144; published online 10 June 2010
INTRODUCTION
Solar UVR is divided into shorter wavelength UVB
(B295–320 nm) and longer wavelength UVA (320–400 nm)
radiation, the vast majority being UVA (typically495%).
UVB is attenuated by the ozone layer, which means that the
ratio of UVB to UVA varies with the height of the sun, which
in turn depends on latitude, season, and time of day. The
quantity of a given waveband is much less important than its
biological efficacy. As a rule of thumb, a given dose of UVB is
approximately 1000 times more erythemogenic than the
same dose of UVA. Thus, the small UVB component of
sunlight is the main cause of erythema and, probably,
nonmelanoma skin cancer.
A sunscreen’s efficacy is measured by its sun protection
factor (SPF), which is a globally accepted index of protection
from erythema after a single exposure to solar simulated
radiation (SSR). SPF is determined under conditions pre-
scribed by authorities such as the European Commission (EC)
or the US Food and Drug Administration. The SSR spectra
specified by regulatory bodies for SPF assessment represent
the sun at high elevation at low latitudes with more UVB
relative to UVA than is found on the equator at noon. The
consequence of this extreme spectrum, coupled with the high
UVB dependence for erythema, is that SPF is primarily a
measure of UVB protection with no quantitative information
of UVA. Increasing concern about the potential adverse long-
term effects of suberythemal UVA has led to the development
of specific indices for UVA protection such as the UVA
protection factor, which is a measure of protection against
persistent pigment darkening, of unknown biological sig-
nificance, or the ratio of UVB and UVA absorption of a
sunscreen. Thus, sunscreens are labeled with SPF plus a
measure of UVA protection. The SPF is only valid as a
measure of protection from erythema and its relationship with
other markers of acute photodamage, such as immunosup-
pression, is unclear (Fourtanier et al., 2005).
The SPF depends on the test UVR spectrum (Farr and Diffey,
1985), and different SSR spectra, compliant with relevant
guidelines, can result in a markedly different SPF (Sayre et al.,
2001). In essence, the higher the UVB content the higher the
labeled SPF. Sunscreen use is widely advocated as a means of
preventing skin cancer, though the empirical human evidence
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to support this advice is either limited or absent (Diffey, 2009).
This is an area of concern because of the increasing incidence
of skin cancer in many white-skinned populations.
In this study, we assess the ability of two sunscreens with
comparable labeled SPFs, but with very different levels of
UVA protection, to prevent cumulative erythema from
repeated daily suberythemal exposure with a nonextreme
SSR source, which is more representative of temperate
latitudes (Christiaens et al., 2005; Seite et al., 2006). Our
experimental design assumes that personal exposure time is
influenced by labeled SPF; there is evidence that people use
sunscreens to prolong intentional sun exposure, but not when
sun exposure is nonintentional (Autier et al., 2007; Autier,
2009). We also modeled SPF at different latitudes and times
of day. This represents changing ratios of UVB to UVA and
their relative contributions to erythema.
RESULTS
Figure 1 shows a typical erythema response from one
volunteer. Erythema intensity increases with time for the
three treatment groups and is most marked with the UVB
sunscreen group. The eye observation shows very little
difference between the no sunscreen and broad-spectrum
sunscreen sites on days 6 and 13. However, the quantitative
erythema data summarized in Figure 2 show more erythema
in sunscreen-treated sites, especially with the UVB sunsc-
reen, than in nonsunscreen-treated controls. There is no
significant difference between control and broad-spectrum
sites on days 6 and 8 (P40.05), but this difference was
significant at day 13 (P¼0.02). There was more erythema in
UVB treated sites compared with the broad-spectrum sites
at all time points (Po0.01). Overall, data show that
photoprotection is much greater with the broad-spectrum
sunscreen. The spectral analysis shown in Table 1a shows
that the UVA erythemally effective energy (EEE) of the UV
daylight (UV-DL) source is about three times higher than that
with a typical European Cosmetics Association (COLIPA)
source. The difference in photoprotection is consistent with
the results given in Table 1b, which shows that the simulated
‘‘SPF’’ of the UVB sunscreen with UV-DL is o50% of its
labeled SPF, as determined in vivo, and approximately 60%
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Figure 1. Typical erythemal responses from one volunteer on days 6 and 13.
The no-sunscreen site was treated with 0.33 minimal erythema dose (MED)
per day and the sunscreen sites were treated with 2 MEDs per day.
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Figure 2. Cumulative erythema on days 6, 8, and 13 measured by
reflectance spectroscopy. Note: days 8 and 13 are measurements from same
sites (right column of Figure 1), whereas day 6 is from the adjacent site given
the same treatments (left column of Figure 1).
Table 1. (a) Spectral analyses of the test UV-DL source
compared with typical COLIPA source and (b)
measured and calculated SPFs under different spectral
conditions
(a)
UV-DL1 COLIPA SSR1
UVA/UVB ratio 26 10.4
Spectral
composition
Spectral
composition
Measured % EEE% Measured %EEE%
UVB (281–320 nm) 3.7 65.7 8.8 87.5
UVA (321–400 nm) 96.3 34.3 91.2 12.5
UVA-I (341–400 nm) 77.7 16.1 70.8 5.1
UVA-II (321–340 nm) 18.6 18.2 20.4 7.4
(b)
Sunscreen SPF
Test condition UVB Broad spectrum
In vivo (COLIPA SSR) 8.6±1.82 7.0±1.62
Simulated UV-DL 3.9 6.7
Simulated (COLIPA SSR) 6.4 6.8
Abbreviations: COLIPA, European Cosmetics Association; EEE, erythe-
mally effective energy; SPF, sun protection factor; SSR, solar simulated
radiation; UV-DL, UV daylight.
1Laboratory of AR Young. See Figure 1 (Seite et al., 2006) for typical
graphical representation.
2Mean±SD.
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of the simulation with a COLIPA-compliant source. Figure 3
shows the modeled SPFs of the two sunscreens at noon at
different latitudes and Figure 4 shows the modeled SPFs of the
two sunscreens at different times of the day at a given
latitude. These data clearly show that the SPF of the broad-
spectrum product is independent of latitude and time of day,
whereas this varies considerably with the UVB product. This
was confirmed by the data in Table 1b, which show that the
SPF of the broad spectrum sunscreen is constant whether
assessed in vivo or with two different spectral simulations.
This is not the case with the UVB sunscreen.
DISCUSSION
We show that the majority UVA content of simulated
temperate solar UVR, given daily in suberythemal doses,
makes a significant contribution to cumulative erythema. This
provides meaningful clinical support for the use of broad-
spectrum sunscreens in the prevention of short-term damage
to the skin, as opposed to persistent pigment darkening,
which has no known biological significance. EEE is the
product of the erythema action spectrum and the emission
spectrum of the UVR source. Our modeled and in vivo
results show that the SPF, and photoprotection from repeated
daily exposure, of a primarily UVB sunscreen is highly
dependent on UVR spectrum, which is not the case with a
broad-spectrum sunscreen. Our simulations show that the
SPF of a UVB sunscreen decreases with increased solar UVR
path. A UVB-enriched source, such as used to label SPF,
enhances the SPF of a primarily UVB sunscreen but
significantly underestimates protection from UVA, especially
in spectral conditions wherein UVA-I makes a relatively
greater contribution to EEE. It should be noted that, although
both sunscreens would carry labels of SPF¼6 in Europe
(European Commission, 2006), the UVB sunscreen had a
higher test SPF (8.6) but provided poorer protection than the
broad-spectrum sunscreen (SPF¼7) under our test condi-
tions.
The advice given by public health bodies is to use a
sunscreen with an SPF of least 15 and avoid the sun for about
2 hours either side of solar noon, when the UVB content is
greatest. Exposure outside this window, or at noon at
temperate latitudes, will result in a relatively greater UVA
EEE. Our modeled data show that the efficacy of a primarily
UVB sunscreen at this time will be much lower than that of
the labeled SPF, even if the sunscreen is applied under the
ideal SPF test condition of 2mg cm2. However, several
studies have shown that people apply much less than that,
correspondingly reducing SPF (Bech-Thomsen and Wulf,
1992; Diffey, 2009).
Our modeled SPF data extend to 501N, which is
equivalent to Southern England. The ‘‘real SPF’’ of a primarily
UVB sunscreen would continue to decrease in more northerly
latitudes, such as Scotland and Scandinavia. This lack of
quantitative and qualitative (spectral) photoprotection
may partly explain why sunscreen use has no or a limited
effect in the prevention of nonmelanoma skin cancer.
Furthermore, this may be particularly relevant to malignant
melanoma in which there is epidemiological and experi-
mental evidence that UVA may have an important role
(Wang et al., 2001; Moan et al., 2008). Indeed it has been
suggested that sunscreen use has increased the risk at
latitudes 4401 because of poor UVA protection (Gorham
et al., 2007).
People use sunscreens to prolong their exposure times for
tanning (Thieden, 2008). We based our exposure times on
labeled SPF (i.e., 6), because this is the only information
available to the consumer for erythema prevention, and we
made the assumption that people would modify their sun
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Figure 3. Effect of latitude on daylight sun protection factor (SPF) at noon.
The value for the broad-spectrum product remains constant, whereas
protection with the UVB sunscreen decreases with increasing latitude. Note
that even on the equator (01), the daylight SPF of the UVB sunscreen is lower
than the SPF obtained in vivo or simulated with a European Cosmetics
Association (COLIPA)-compliant source. This is because the COLIPA source
has more UVB than solar UVR, even under extreme conditions.
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Figure 4. Effect of time of day on daylight sun protection factor (SPF) at
101N (e.g., well within the Tropic of Cancer). The value for the broad-
spectrum product remains constant, whereas protection with the UVB
sunscreen decreases either side of noon. Note that even at noon the daylight
SPF of the UVB sunscreen is lower than the SPF obtained in vivo or simulated
with a European Cosmetics Association (COLIPA)-compliant source. This is
because the COLIPA source has more UVB than solar UVR, even under
extreme conditions.
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exposure behavior in response to this. We thus increased
exposure times sixfold with the sunscreens, when compared
with no application. Our daily UVR exposures are realistic
with and without sunscreens. The standard erythema dose is a
way of comparing exposures that is independent of minimal
erythema dose (MED) and UVR spectrum. Values of 0.33
MED (no sunscreen) and 2 MED (with sunscreen) are
equivalent to approximately 1 and 6 standard erythema
doses, respectively, in skin types I/II. Typically, the face is
exposed to approximately 1 standard erythema dose at
weekends in summer in Northern Europe (Diffey, 2008).
However, studies using time-stamped personal electronic
dosimeters show that much higher doses can be obtained in
Northern Europe (4501N) in summer, with many people
having exposures of X10 standard erythema doses on some
days (Thieden et al., 2004). It could be argued that higher
SPFs should have been used because this is recommended by
public health authorities. However, we were restricted by the
threefold longer time it takes to induce erythema with the
spectrum we used compared with a typical spectrum for SPF
testing. Thus, higher labeled SPFs would have resulted in
unacceptably long exposure times for the study volunteers.
On the other hand, SPF 6 is the minimal protective
requirement for a preparation to be claimed as a sunscreen
in Europe. In mitigation, we applied the sunscreen under SPF
test conditions of 2mg cm2 which has resulted in much
better protection than that obtained under typical consumer
use of o1mg cm2 (Schalka et al., 2009).
Few comparable studies have been carried out in humans.
One showed that two sunscreens with the same low SPF
(¼ 4), but with quite different absorption spectra, gave
comparable protection from epidermal DNA photodamage
after a single exposure (Young et al., 2000). Another, with
two SPF¼15 sunscreens with different spectral properties,
showed that the broad-spectrum product afforded greater
immunoprotection than a product with less UVA protection
(Moyal and Fourtanier, 2003). Overall, UVA protection
seems to be important in immunoprotection (Young, 2003).
Seite et al. (2006), reported significantly increased erythema
with nine repeated doses of 0.25 MED UV-DL given over
2 weeks. Our data confirm this; a daily 0.33 MED of UV-DL
without sunscreen resulted in an accumulation of erythema
as measured using reflectance spectroscopy, but this was
minimally detectable by eye.
We did not evaluate molecular and cellular damage.
However, broad-spectrum sunscreens have been shown to
inhibit some possible biomarkers for skin cancer and
photoaging after repeated suberythemal exposure with
extreme (Seite et al., 2009) and temperate (Seite et al.,
2009) solar simulation. A similar approach to ours has been
taken in one study using reconstructed human skin exposed
to single exposures of UV-DL with sunscreens of the same
SPF (B15), but with different spectral properties. This showed
that the broad-spectrum sunscreen gave much better protec-
tion from the induction of matrix metalloproteinase-1 protein
(Lejeune et al., 2008). However, we need studies that
compare these effects with products of the same SPF but
with different spectral properties in human skin in vivo.
The sunscreen industry has developed in vivo and in vitro
methods to show UVA protection, and these have been
adopted by the EC and the Food and Drug Administration.
In vivo techniques have been based on the prevention
of persistent pigment darkening, the clinical significance
of which is unlikely to be important. Such testing results in a
UVA index of protection, as well as SPF labelling on
products, and may confuse users because sunscreens can
have high levels of UVA protection with a relatively low SPF.
Our data suggest that it might be better to base protection on
a single in vivo measure but with a requirement for
sunscreens to be truly broad spectrum.
In summary, we show that labeled SPF is not a good
indicator of photoprotection and our data support the use of
broad-spectrum sunscreens from a biological and consumer
protection point of view. Of particular note is the lack of SPF
dependence on latitude or time of day, resulting in a more
robust index of protection. The SPF applies only to erythema
and requires the development of other indices of protection,
such as UVA protection factor and immune protection factor.
A broad-spectrum sunscreen is a neutral density filter and
under these conditions an SPF will apply to a wide range of
acute end points that are independent of emission spectra and
wavelength dependence. Finally, our data show that the
classification of sunscreens by their ability to inhibit erythema
from a single exposure, as indicated by the SPF test, does not
result in the abrogation of inflammation from repeated
suberythemal exposure. Inflammation is a known contribu-
tory factor in cancer and it may be necessary to educate the
public in the correct use of sunscreens or encourage the use
of very high SPF to compensate for low application density.
MATERIALS AND METHODS
Sunscreens
Two sunscreens were formulated by CIBA (now part of BASF), Basel,
Switzerland with the concentrations of the active ingredients
determined by the CIBA (now BASF) sunscreen simulator (BASF
Schweiz, 2009) to comply with a labeled SPF of 6 as described by
EC recommendations (European Commission, 2006), and supplied
in a double-blind manner. One was a UVB filter with 4% ethylhexyl
methoxycinnamate and the other was a broad-spectrum filter
with 1.65% methylene bis-benzotriazolyl tetramethylbutylphenol
and 0.88% bis-ethylhexyloxyphenol methoxyphenyl triazine. The
sunscreens’ in vivo SPFs, determined by an independent laboratory
according to the COLIPA protocol, were 8.6 (±1.8 (SD)) and 7.0
(±1.6 (SD)), respectively (significantly different; 2-tailed t-test,
P¼ 0.02), and would therefore both be labeled with SPF¼ 6
according to EC recommendations. Their in vitro UVA protection
factors determined according to the method suggested by COLIPA
(COLIPA, 2007) were 1.1 (±0.1 (SD)) and 6.5 (±0.2 (SD)),
respectively. The in vitro transmission spectra after adjustment for
their respective in vivo SPF are shown in Figure 5. The same
adjustment was used to calculate the UVA/UVB ratio (Diffey, 1994),
which was 0.14 (0* according to the Boots system (Brown, 2005)) for
the UVB sunscreen and 0.91 (5*) for the broad-spectrum sunscreen.
The EC recommendations for a sunscreen product require a UVA
protection factor of at least one-third of the SPF and a critical
wavelength greater than 370 nm (European Commission, 2006).
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However, in the case of the UVB formulation, an SPF may still be
claimed for a cosmetic daycare product without UVA protection.
The SPFs of the sunscreens under different UVR spectral conditions
were also calculated using the CIBA (now part of BASF) sunscreen
simulator (BASF Schweiz, 2009). The basis of this calculation is
given by Eq. 1 (Sayre et al., 1979).
SPF ¼
P400
290
serðlÞ  SsðlÞ
P400
290
serðlÞ  SsðlÞ  T ðlÞ
ð1Þ
where Ss(l) is the spectral irradiance, ser(l) the CIE erythema action
spectrum and T(l) the transmission of the sunscreen. Data for Ss(l) and
ser(l) are available in the literature (McKinlay and Diffey, 1987; Diffey
and Robson, 1989), but T(l) has to be determined for the respective
sunscreen. The simulation program calculates the overall absorbance
spectrum of the sunscreen from the UVR absorbance spectra of the
individual UVR absorbers according to their quantities in the
formulation. The transmission of the sunscreen T(l) is obtained from
that overall absorbance taking into account the irregularity of the
sunscreen film. In addition, the dynamic change of T(l) due to
photoinstability of some UVR absorbers is considered (Herzog et al.,
2004; Herzog, 2008). Dr John Frederick of the University of Chicago
generously provided computed UVR spectral irradiances for the month
of July at latitudes 501S (e.g., Southern Chile), 301S, 101S, 101N,
301N, and 501N (e.g., Southern England) made at half-hour intervals
through the course of a day (Christiaens et al., 2005). These data were
used to calculate SPF under different solar spectrum conditions.
Standard UV-DL
We simulated solar radiation to represent nonextreme conditions
based on Christiaens et al. (2005). This was carried out with a solar
simulator (model 81292, L.O.T Oriel, Leatherhead, UK) with a 1-kW
xenon arc lamp and two dichroic mirrors, a collimator and a 2mm
Schott AG (Mainz, Germany) WG 320 filter. The emission spectrum
of this standard UV-DL was determined with a DM150BC double
monochromator spectroradiometer (Bentham Instruments, Reading,
UK), using an integration sphere and gratings blazed at 250 nm. This
instrument was calibrated using a deuterium lamp that had been
calibrated by the National Physical Laboratory (Teddington,
England). The emission spectrum typical of the UV-DL spectrum is
shown in Figure 1 of Seite et al. (2006). A waveband analysis of our
spectrum and of a typical SSR spectrum including EEE is given in
Table 1a. This shows a much higher UVA/UVB ratio in the UV-DL
spectrum and that UV-DL UVA has a 2.7-fold greater contribution to
erythema than does SSR UVA. This difference in EEE is approxi-
mately the same for UVA-I (3.2-fold) and UVA-II (2.5-fold).
Volunteers and study protocol
This study was approved by the St Thomas’ Hospital Research Ethics
Committee, London, UK and was compliant with the Declaration of
Helsinki Principles. Participants gave written informed consent.
Individual just-perceptible MED was determined on previously
unexposed buttock of sun-sensitive skin phototype I/II healthy
volunteers (mean age 28±4 (SD) years, two males and six females)
using a dose series with 25% increments. Routine dosimetry was
carried out with an International Light Technologies Inc. (Peabody,
MA) IL 1400 radiometer that had been calibrated against the
spectroradiometric measurements. Three test sites were identified on
the contralateral buttock of each volunteer. Sunscreen was applied
at 2mg cm2 over a delineated area of 9 5 cm, with one sunscreen
site above the control site and the other below. The skin was
exposed to UV-DL about 20minutes later. Each exposure was
carried out in duplicate over an area of 1 cm2, with a space of 1 cm
between any two treatments, using a template made from kitchen
foil and double-sided sticky tape. The layout can be seen from the
erythema results given in Figure 1. Mean MED was 14.3 J cm2
(±2.9 (SD)), of which 0.53 J cm2 (±0.11) was in the UVB
(280–320nm) region. The control sites were exposed to 0.33
individual MED UV-DL per day for 13 consecutive days. The
sunscreen sites were exposed to two individual MED for 13
consecutive days. This represents six times the control dose based
on the labeled SPF of 6 of the products.
Quantitative measurements of erythema (arbitrary units) were
determined in triplicate before sunscreen application and/or UV-DL
exposure using a reflectance meter (Diastron, Andover, UK) at
days 6, 8, and 13. Erythema increase at each site was calculated
by subtracting the mean background reading taken from
adjacent nonirradiated skin. Induction of erythema is expressed as
D erythema index.
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